Late-phase trial failure for GSK, Prosensa muscular dystrophy drug

09/23/2013 | PharmaTimes (U.K.)

A Phase III trial for drisapersen, a drug by GlaxoSmithKline and Prosensa for treating Duchenne muscular dystrophy, failed to meet primary goals three months after receiving breakthrough therapy designation from the U.S. FDA. The trial among 186 boys suffering from the disease failed to demonstrate significant improvement in walking distance or motor function, compared with a placebo. DMD affects one in 3,500 live male births.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR